Keywords: nice, rejects, gsk, tyverb, too, expensive, second

NICE rejects GSK's Tyverb as too expensive in second draft recommendation

Article | 20 October 2008

Print This

Tyverb (lapatinib) has been deemed too expensive for use by the UK's National Health Service, despite an offer from drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in